Arbutus Biopharma
ABUS | NASDAQ
$4.04
-$0.05 (-1.22%)
At close: Nov 16, 2026, 4:00 PM ET
$4.17
+$0.13 (+3.22%)
After-hours:
Nov 16, 2026, 7:33 PM ET
Arbutus Biopharma Company Profile
Company profile explainedCompany Profile
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Lindsay Androski | President, Chief Executive Officer & Chairman |
| Tuan Nguyen | Chief Financial Officer |
| Andrew J. Sung | General Counsel |
| R. Hector Mackay-Dunn | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2026 | 8-K | Current Report |
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 05, 2026 | SC 13D/A | [Amend] Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 01, 2026 | SC TO-I/A | [Amend] Filing |
Arbutus Biopharma
| Country | United States |
| IPO Date | Jul 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Lindsay Androski |
Contact Details
701 Veterans Circle Warminster,
Pennsylvania 18974 United States
Stock Details
| Ticker Symbol | ABUS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001447028 |
| CUSIP Number | 03879J100 |
| ISIN Number | CA03879J1003 |
| SIC Code | 2834 |
Recent News
- 3 months ago / globenewswire.comArbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Add to Watchlist
Select watchlists to add or remove ABUS